SPRY Share Price Performance
US$8.03
-5.37 (-40.07%)
70.3% undervalued intrinsic discount
US$27.00
Fair Value
Price US$8.03
AnalystConsensusTarget US$27.00
AnalystLowTarget US$12.00
AnalystHighTarget US$40.00
Fair ValueUS$27.00
Share Pricen/a
ARS Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 56 Fair Values set on narratives written by author
SPRY Community Narratives
AN
Fair Value US$27 69.3% undervalued intrinsic discount
Worldwide Allergy Trends Will Expand Needle-Free Treatment Access
0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
AN
Fair Value US$12.08 31.3% undervalued intrinsic discount
Costs And Regulation Will Hinder Prospects But Demand Will Recover
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value US$40 79.3% undervalued intrinsic discount
Needle-Free Allergy Therapies Will Capture Untapped Global Markets
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Costs And Regulation Will Hinder Prospects But Demand Will Recover
Key Takeaways Heavy reliance on neffy leaves ARS vulnerable to regulatory pressures, payer negotiations, and potential product setbacks impacting future growth and revenue sustainability. Intensifying competition, pricing pressure, and uncertain access to capital threaten margin stability, expansion plans, and investment in long-term pipeline diversification.Read more
54
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$12.08
31.3% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
30.2x
Price in 2029
US$14.87
Worldwide Allergy Trends Will Expand Needle-Free Treatment Access
Key Takeaways Accelerating demand and expanded access for neffy, especially in pediatric and school settings, is driving significant revenue and earnings growth opportunities. Global expansion, new clinical indications, and strong market penetration strategies are broadening revenue streams and creating multiple long-term growth drivers.Read more
353
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
AN
US$27
69.3% undervalued intrinsic discount
Fair Value
Profit Margin
5.7%
Future PE
139.98x
Price in 2029
US$33.24
Needle-Free Allergy Therapies Will Capture Untapped Global Markets
Key Takeaways Neffy's needle-free delivery is expanding the allergy treatment market, attracting previously untreated patients and driving greater-than-expected revenue and prescription growth. Enhanced insurance coverage, multi-pack purchasing, and strategic positioning are accelerating recurring sales, expanding margins, and making ARS attractive for global partnerships or acquisition.Read more
42
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$40
79.3% undervalued intrinsic discount
Fair Value
Profit Margin
19.17%
Future PE
43.45x
Price in 2028
US$48.29
Trending Discussion
Recently Updated Narratives
AN
SPRY: Rival FDA Setback Will Support Future Anaphylaxis Market Upside
Fair Value: US$12.08 31.3% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SPRY: Competitor FDA Setback Will Support Future Upside Potential
Fair Value: US$27 69.3% undervalued intrinsic discount
20 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Needle-Free Allergy Therapies Will Capture Untapped Global Markets
Fair Value: US$40 79.3% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ARS Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.73
- 60.13%
- -203.25%
- 147.5%
About SPRY
- Founded
- 2015
- Employees
- 161
- CEO
- WebsiteView website
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
